Journals / Erciyes Tıp Dergisi / 2004 / Cilt: 26 - Sayı: 4

Immunohistochemical cathepsin-D expression in breast carcinoma: Correlation with prognostic factors and survival

Meme kanserinde immünohistokimyasal olarak cathepsin-D ekspresyonu: Diğer prognostik faktörlerle ve sağkalımla ilişkisi

Pages
178–185
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After a median follow up of 33 months, CD positivity showed significant correlation with disease free survival (p=0.011) but not with overall survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Breast cancer is an increasingly important cause of illness and death among women.
📊
Key Findings & Data:Material and methods: CD protein expression was analysed immunohistochemically in tumor specimens of 64 breast cancer patients.
💡
Conclusion & Impact:After a median follow up of 33 months, CD positivity showed significant correlation with disease free survival (p=0.011) but not with overall survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Breast cancer is an increasingly important cause of illness and death among women. In recent years, several prognostic determinents of breast cancer have been identified, including Cathepsin-D (CD). Material and methods: CD protein expression was analysed immunohistochemically in tumor specimens of 64 breast cancer patients. Results: CD expression was determined in 68.7% of the cases, and immunoreaction was strong in 45.3% of the cases. There was a significant correlation between stage (p=0.01) and c-erbB-2 immunorectivity (p=0.017). After a median follow up of 33 months, CD positivity showed significant correlation with disease free survival (p=0.011) but not with overall survival. Conclusions: CD expression is related to recurrence and metastatic potential of breast cancer. In addition, CD expression may be acquired in the preinvasive stage of the carcinoma, since there was CD immunoreactivity in adjacent insitu ductal carcinoma, areas of strongly immunoreactive invasive carcinomas.

Özet

Amaç: Meme kanseri kadın popülasyonda önemi günden güne artan hastalık ve ölüm nedenidir. Son yıllarda Cathepsin-D (CD) gibi çeşitli prognostik belirleyiciler önem kazanmıştır. Gereç ve yöntem: CD protein immunreaktivitesi 64 meme kanserli hastada immünohistokimyasal olarak belirlendi. Bulgular: CD ekspresyonu vakaların %68.7"sinde izlendi, %45.3'ünde ise immünreaksiyon şiddetli idi. CD ekspresyonu ile tümör evresi (p-0.01) ve c-erbB-2 immunreaktivitesi (p=0.017) arasında anlamlı ilişki elde edildi. Ortalama 33 ay izlem sonrası CD ekspresyonu ile hastalıksız sağ kalım arasında anlamlı ilişki elde edildi (p= 0.011). Genel sağ kalım süresi ile CD ekspresyonu anlamlı bir ilişki göstermedi. Sonuç: CD ekspresyonunun nüks ve metastatikpotansiyel ile yakından ilişkili olduğu sonucuna varılmıştır. Ayrıca kuvvetli immünreaksiyon gösteren tümörlerin komşu insitu duktal karsinom sahalarında da immünreaksiyon olması, meme karsinomlarında CD ekspresyonunun preinvaziv dönemde kazanılmış olabileceğini desteklemektedir.

🔖

Cite This Article

SOYUER, S., ÖZKAN, M., ÖZTÜRK, F., CANÖZ, Ö., DENİZ, K., AKGÜN, H., KÜÇÜK, C. (2022). Immunohistochemical cathepsin-D expression in breast carcinoma: Correlation with prognostic factors and survival. Erciyes Tıp Dergisi, Cilt: 26 - Sayı: 4, 178–185. https://ajindex.com/articles/502838

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell. 1980; 20: 353- 62
  2. Isola J, Weitz S, Visakorpi T, et al. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol. 1993;11: 36-43
  3. Takei Y, Higashira H, Yamamoto T, Hayashi K. Mitogenic activity toward human breast cancer cell line MCF-7 of two bFGFs purified from sera of breast cancer patients: co-operative role of cathepsin D. Breast Cancer Res Treat. 1997; 43: 53-63
  4. Losch A, Tempfer C, Kohlberger P, et al. Prognostic value of cathepsin D expression and association with histomorphological subtypes in breast cancer. Br J Cancer. 1998; 78: 205-9
  5. Henry JA, McCarthy AL, Angus B, et al. Prognostic significance of the estrogen- regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer. 1990; 15; 65: 265-271
  6. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node negative breast cancer A review of studies with sample size more than 200 and follow-up more than 5 years. Annals of Surgery. 2002; 235:10-16
  7. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 3;72: 1-22
  8. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer. 1997; 76: 661-666
  9. Foekens JA, Look MP, Bolt-de Vries J, Meijer van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79: 300-307
  10. Roger P, Daures JP, Maudelonde T, et al. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. Hum Pathol. 2000; 31: 593- 600
  11. Aziz S, Pervez S, Khan S, Kayani N, Rahbar M. Immunohistochemical cathepsin-D expression in breast cancer: correlation with established pathological parameters and survival. Pathol Res Pract 2001;197: 551-557
  12. Zhao H, Morimoto T, Sasa M, Tanaka T, Izumi K. Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast. Breast Cancer. 2002; 9: 118-126
  13. Korkolis D, Ardavanis A, Yotis J, Kyroudi A, Gorgoulis V, Kittas C. HER-2/neu overexpression in breast cancer: an imm